Results for: Breast

67 Trials Avaliable

  • BRE 203

    A Phase II trial with TAK -700 in Metastatic breast cancer patients with tumors that express the Androgen Receptor (AR)

  • BRE 220

    A PHASE Ib OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF GDC-0032 IN COMBINATION WITH EITHER DOCETAXEL OR PACLITAXEL IN PATIENTS WITH HER2-NEGATIVE, LOCALLY RECURRENT OR METASTATIC BREAST CANCER

  • BRE 225

    A phase 1, open-label, dose escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer

  • BRE 226

    A phase Ib/II, multicenter, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer

  • BRE 231

    A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The 'METRIC' Study)

  • BRE 237

    A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician's Choice in Germline BRCA Mutation Subjects with Locallky Advanced and/or Metastatic Breast Cancer, Who Have Received No More than 2 Prior Chemotherapy Regiments for Metastatic Disease

  • BRE 239

    A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer

  • BRE 243

    A phase Ib/II study of LEE011 in combination with fulvestrant and BYL719 or BKM120 in the treatment of postmenopausal women with hormone receptor positive, HER2 negative locally recurrent or advanced metastatic breast cancer

  • BRE 249

    A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician's Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer

  • BRE 253

    A Phase I/II Multicenter Study of the Combination of AZD2014 and Palbociclib on a background of Hormonal Therapy in Patients with Locally Advanced/Metastatic Estrogen Receptor Positive Breast Cancer Comprising a Safety, Pharmacokinetic and Preliminary Efficacy Evaluation followed by a Randomized, Double-Blind, Placebo-controlled, Parallel Group Extension (PASTOR)

  • BRE 257

    A randomized Phase 2 Study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer

  • BRE 258

    A PHASE III, MULTICENTER, RANDOMIZED PLACEBO-CONTROLLED STUDY OF MPDL3280A (ANTI?PD-L1 ANTIBODY) IN COMBINATION WITH NAB PACLITAXEL COMPARED WITH PLACEBO WITH NAB PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE NEGATIVE BREAST CANCER

  • BRE 259

    A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer

  • BRE 260

    A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs.Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapiesand Require Systemic Treatment

  • BRE 261

    A PHASE Ib, TWO-ARM, NEOADJUVANT STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION ADO TRASTUZUMAB EMTANSINE AND PERTUZUMAB OR TRASTUZUMAB AND PERTUZUMAB IN TREATMENT-NAIVE PATIENTS WITH OPERABLE OR LOCALLY ADVANCED HER2 POSITIVE EARLY BREAST CANCER

  • BRE 262

    A Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna' in Early Stage Breast Cancer Patients who would be Normal Candidates for Genomic Testing

  • BRE 263

    The impact of HER2 heterogeneity on the treatment of early-stage HER2-positive breast cancer: a phase II study of T-DM1 in combination with Pertuzumab in the preoperative setting

  • BRE 265

    An Open-Label, Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

  • BRE 267

    A phase III randomized double-blind, placebo-controlled study of alpelisib in combination with fulvestrant versus placebo plus fulvestrant as first- or second-line treatment for postmenopausal women and men with hormone receptor positive, HER2-negative, advanced breast cancer previously treated with endocrine therapy

  • BRE 268

    An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)

  • BRE 269

    Phase Ib dose-escalation trial of Taselisib (GDC-0032) in combination with anti-HER2 therapies in participants with advanced HER2+ Breast Cancer

  • BRE 270

    Randomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE-1)

  • BRE 271

    Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

  • BRE 272

    A Phase 2, randomized, multicenter, 3-arm, open-label study to compare the efficacy of abemaciclib plus trastuzumab plus fulvestrant and abemaciclib plus trastuzumab to standard of care single agent chemotherapy of physician's choice plus trastuzumab with respect to progression free survival in patients with HR+, HER2+ metastatic breast cancer

  • BRE 273

    A randomized controlled multicenter Phase IIa trial to evaluate the safety and immunogenicity of two doses of vaccination with Folate Receptor Alpha peptides with GM-CSF in patients with Triple Negative Breast Cancer

  • BRE 274

    A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer

  • BRE 277

    A Phase 1, Two-Cohort, Open-Label, Drug- Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women with Locally Recurrent or Metastatic ER+ Breast Cancer

  • BRE 278

    A Randomized, Open-Label, Phase 2 Study of Abemaciclib plus Tamoxifen or Abemaciclib Alone, in Women with Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer

  • BRE 280

    A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB EMTANSINE IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY, EITHER ALONE OR IN COMBINATION

  • BRE 281

    Palbociclib and Endocrine therapy for LObular breast cancer Preoperative Study: A randomized phase II study of Palbociclib with letrozole versus letrozole alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma

  • BRE 283

    A PHASE 3 OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY OF NKTR-102 VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN PATIENTS WITH METASTATIC BREAST CANCER WHO HAVE STABLE BRAIN METASTASES AND HAVE BEEN PREVIOUSLY TREATED WITH AN ANTHRACYCLINE, A TAXANE, AND CAPECITABINE

  • BRE 285

    A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF GDC-0077 AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE AND TARGETED THERAPIES IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT HORMONE-RECEPTOR POSITIVE BREAST CANCER

  • BRE 286

    A Phase 1b Study Followed by an Open label, Parallel, Randomized Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of GS-5829 in Combination with Exemestane or Fulvestrant Comparing with Exemestane or Fulvestrant Alone in Subjects with Advanced Estrogen Receptor Positive HER2- Breast Cancer

  • BRE 287

    A Phase I-II multicenter, open label trial of H3B-6545, a covalent antagonist of estrogen receptor alpha, in women with locally advanced or metastatic estrogen receptor-positive, HER2 negative breast cancer

  • BRE 288

    Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy

  • BRE 290

    An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptorpositive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease Authors

  • BRE 292

    A PHASE 1, FIRST-IN-HUMAN, MULTI-PART STUDY OF RAD140 IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE BREAST CANCER

  • BRE 293

    A PHASE III RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NEOADJUVANT ANTHRACYCLINE-BASED CHEMOTHERAPY COMPARED WITH PLACEBO AND CHEMOTHERAPY IN PATIENTS WITH PRIMARY INVASIVE TRIPLE-NEGATIVE BREAST CANCER

  • BRE 294

    A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER-2-negative, early breast cancer with high risk of relapse

  • BRE 296

    A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

  • BRE 297

    A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER

  • BRE 298

    An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic (Stage IV) Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments

  • BRE 300

    A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH HORMONE RECEPTOR'{POSITIVE HER2-NEGATIVE BREAST CANCER (MORPHEUS-HR+ BREAST CANCER)

  • BRE 302

    Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low HER2 expression MBC

  • BRE 303

    A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane

  • BRE 303

    A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane

  • BRE 304

    A phase III, randomized, placebo-controlled, multicenter study of the efficacy and safety of atezolizumab plus chemotherapy in the treatment of early-relapsing locally recurrent inoperable or metastatic triple-negative breast cancer

  • BRE 305

    An Open Label Study of SC-005 in Subjects with Triple Negative Breast Cancer (TNBC)

  • BRE 308

    AN OPEN-LABEL, SINGLE-ARM PILOT STUDY EVALUATING THE ANTITUMOR ACTIVITY AND SAFETY OF NIRAPARIB AS NEOADJUVANT TREATMENT IN LOCALIZED, HER2-NEGATIVE, BRCA-MUTANT BREAST CANCER PATIENTS

  • BRE 311

    A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING DOSES OF DHES0815A IN PATIENTS WITH HER2-POSITIVE BREAST CANCER

  • BRE 314

    A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination with Palbociclib in Women with Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

  • BRE 317

    A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF DS-8201A, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS ADO-TRASTUZUMAB EMTANSINE (T-DM1) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH TRASTUZUMAB AND TAXANE

  • BRE 320

    A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

  • MULTI 18

    A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment with Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic Disease

  • OUTCOMES 02

    Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane use in Metastatic Breast Cancer

  • PRO 09

    A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

  • REFMAL 275

    AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC 0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HORMONE

  • REFMAL 424

    Phase 1/2 Trial of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

  • REFMAL 456

    A Phase 1b, First in Human, Dose Escalation and Expansion Study of XMT-1522 in Patients with Advanced Breast Cancer and Other Advanced Tumors Expressing HER2

  • REFMAL 530

    OPEN-LABEL, DOSE ESCALATION PHASE IB STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF RO6870810 AND ATEZOLIZUMAB (PD-L1 ANTIBODY) IN PATIENTS WITH ADVANCED OVARIAN CANCER OR TRIPLE NEGATIVE BREAST CANCER

  • REFMAL 530

    OPEN-LABEL, DOSE ESCALATION PHASE IB STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF RO6870810 AND ATEZOLIZUMAB (PD-L1 ANTIBODY) IN PATIENTS WITH ADVANCED OVARIAN CANCER OR TRIPLE NEGATIVE BREAST CANCER

  • REFMAL 534

    A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple-Negative Breast Cancer and Hepatocellular Carcinoma

  • REFMAL 566

    A PHASE 1B, MULTICENTER, TWO-PART, OPENLABEL STUDY OF DS-8201A, AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2)-ANTIBODY DRUG CONJUGATE (ADC), IN COMBINATION WITH NIVOLUMAB, AN ANTI-PD-1 ANTIBODY, FOR SUBJECTS WITH HER2- EXPRESSING ADVANCED BREAST AND UROTHELIAL CANCER

  • REFMAL 566

    A PHASE 1B, MULTICENTER, TWO-PART, OPENLABEL STUDY OF DS-8201A, AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2)-ANTIBODY DRUG CONJUGATE (ADC), IN COMBINATION WITH NIVOLUMAB, AN ANTI-PD-1 ANTIBODY, FOR SUBJECTS WITH HER2- EXPRESSING ADVANCED BREAST AND UROTHELIAL CANCER

  • REFMAL 588

    A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES AND TREATMENT INTENSIFICATION OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN-2 (VBIR-2) (PF-06936308) FOR ADVANCED NON-SMALL CELL LUNG CANCER AND METASTATIC TRIPLE-NEGATIVE BREAST CANCER

  • Tissue 03

    Collection of 500 mg fresh tumor tissues from Bre

  • Tissue 04

    Breast Cancer Stage III FFPE slides with matched plasma